Cargando…
A gene responsible for prolyl-hydroxylation of moss-produced recombinant human erythropoietin
Recombinant production of pharmaceutical proteins is crucial, not only for personalized medicine. While most biopharmaceuticals are currently produced in mammalian cell culture, plant-made pharmaceuticals gain momentum. Post-translational modifications in plants are similar to those in humans, howev...
Autores principales: | Parsons, Juliana, Altmann, Friedrich, Graf, Manuela, Stadlmann, Johannes, Reski, Ralf, Decker, Eva L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804855/ https://www.ncbi.nlm.nih.gov/pubmed/24145658 http://dx.doi.org/10.1038/srep03019 |
Ejemplares similares
-
Glyco-engineering for biopharmaceutical production in moss bioreactors
por: Decker, Eva L., et al.
Publicado: (2014) -
Moss‐made pharmaceuticals: from bench to bedside
por: Reski, Ralf, et al.
Publicado: (2015) -
O-methylated N-glycans Distinguish Mosses from Vascular Plants
por: Stenitzer, David, et al.
Publicado: (2022) -
Process Engineering of Biopharmaceutical Production in Moss Bioreactors via Model-Based Description and Evaluation of Phytohormone Impact
por: Ruiz-Molina, Natalia, et al.
Publicado: (2022) -
Recombinant Production of MFHR1, A Novel Synthetic Multitarget Complement Inhibitor, in Moss Bioreactors
por: Top, Oguz, et al.
Publicado: (2019)